The midazolam half life elimination of IM administration is comparable to that observed following the IV administration.
Midazolam is approximately 97% plasma protein-bound in normal subjects. In patients with chronic renal failure, the free fraction of drug in plasma can be significantly higher than in healthy adults.
In animals and humans, Midazolam has shown to cross the placenta and to enter into the foetal circulation. Clinical data indicate that midazolam is excreted through breast milk.
The kinetics in critically ill patients with multi-system dysfunction is unpredictable and it is recommended that midazolam half life be titrated to the desired effect.
The elimination midazolam half life was longer following continuous infusion in ICU patients 6 following the injection of single IV doses. Steady-state plasma levels increased with increasing rates of infusion.